首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1917876

生物分析檢測市場－2026-2031年預測

Bioanalytical Testing Market - Forecast from 2026 to 2031

出版日期: 2026年01月08日 | 出版商:

Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計生物分析測試市場將從 2025 年的 40.14 億美元成長到 2031 年的 96.31 億美元，複合年成長率為 15.7%。

生物分析檢測市場是製藥和生命科學產業中重要且不斷成長的細分市場，其成長主要得益於其在藥物研發和個人化醫療中的關鍵作用。該市場涵蓋對血液、血漿、尿液和組織等生物基質中的藥物、代謝物、生物標記和其他分析物的定量檢測。其持續成長的動力來自科學、醫學和行業趨勢的共同作用，包括個人化醫療的興起、持續的技術創新以及全球不斷成長的候選藥物和臨床試驗項目。

市場擴張的關鍵促進因素是對個人化醫療和生物標記主導藥物研發日益成長的需求。隨著治療策略越來越注重根據患者的基因資訊、疾病特徵和預測反應來客製化治療方法，對先進生物分析的需求變得至關重要。生物分析檢測對於識別和檢驗生物標記、量化標靶結合以及闡明特定患者亞群的藥物動力學/動態(PK/PD) 關係至關重要。這種從「一刀切」模式轉向精準醫療的轉變需要更複雜、更靈敏、更特異的分析方法，從而直接推動了對先進檢測服務和專業知識的需求，以支持標靶治療和伴隨診斷。

同時，分析技術的不斷進步正在提升生物分析檢測的能力和效率。高解析度質譜（HRMS）和超高效液相層析法（UHPLC）等儀器創新，結合先進的配體結合分析平台，不斷提高檢測的靈敏度、特異性和通量。自動化、機器人技術和先進數據分析的整合簡化了工作流程，減少了人為誤差，並加快了結果的獲取速度。這些技術進步使研究人員能夠應對更具挑戰性的分子，例如大規模生物製藥、細胞和基因療法以及寡核苷酸，同時產生高品質的數據。這正在推動這些技術在研究和監管檢測中得到更廣泛的應用，並催生出更具雄心壯志的應用。

此外，全球藥物研發活動的持續成長以及慢性病盛行率的不斷上升也推動了市場的發展。日益加重的疾病負擔，包括癌症、代謝失調和心血管疾病，使得開發新型療法變得特別迫切。這反過來又推動了大量臨床前和臨床項目的研發，而每個項目都需要廣泛的生物分析支援。從早期候選藥物篩檢和先導藥物最適化到關鍵性臨床試驗和上市後監測，檢測在整個研發過程中至關重要。臨床研究的擴展，包括複雜的研究設計和跨地域的研究，顯著增加了檢測需求的數量和地理範圍，從而為服務供應商提供了穩定的需求基礎。

從地理上看，北美在生物分析檢測市場佔據主導地位。這一優勢歸功於該地區高度集中的製藥和生物技術研發生態系統、高水準的臨床試驗活動以及對生命科學研發的大量投資。成熟的大規模受託研究機構(CRO)、專業檢測實驗室和先進學術研究中心網路，創造了緊密聯繫且競爭激烈的服務環境。該地區清晰的監管路徑和對新型治療方法的早期應用，進一步鞏固了其作為先進生物分析營運中心的領先地位。

儘管成長要素強勁，但市場仍面臨諸多限制因素，影響其營運和經濟效益。依照監管申報所需的嚴格標準進行生物分析檢測成本高。這些成本主要來自精密的分析設備、高技能人員、昂貴的試劑和參考標準品，以及全球衛生當局強制執行的嚴格品管和驗證流程。此外，取得某些高品質生物樣本，特別是針對罕見疾病和特殊患者群體的樣本，可能帶來後勤和倫理方面的挑戰，從而延誤調查。另外，應對不斷變化的區域監管要求也增加了營運負擔和成本，要求檢測服務提供者保持高度警覺並不斷調整。

競爭格局的特點是大規模全方位服務的合約研究組織 (CRO)、專業分析實驗室以及大型製藥企業的內部檢測能力並存。關鍵差異化因素包括複雜檢測法的技術專長、完善的品質和合規體系、全球企業發展以及端到端的一體化服務交付能力。申辦方與試驗服務提供者之間建立策略聯盟，以充分利用專業知識並管理大型或技術複雜專案的資源，正逐漸成為主流。

總之，生物分析檢測市場正與藥物發現和開發領域的整體變革同步發展。其發展軌跡與產業向精準醫療、複雜生物製藥和加速開發路徑的轉型緊密契合。未來成長將得益於不斷突破可衡量範圍和速度極限的技術創新，以及治療藥物研發的持續進步。市場參與企業的成功取決於其能否不斷調整自身以支持下一代變革性治療方法，並在科學卓越性、監管嚴謹性和營運效率之間取得平衡。

本報告的主要優勢：

深入分析：提供對主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
競爭格局：了解全球主要參與者的策略舉措，並了解透過正確的策略實現市場滲透的潛力。
市場促進因素與未來趨勢：探索推動市場的動態因素和關鍵趨勢，以及它們將如何塑造未來的市場發展。
可操作的建議：利用這些見解，在動態環境中做出策略決策，並開拓新的商機和收入來源。
受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

您打算如何使用這份報告？

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

2021年至2025年的歷史數據和2026年至2031年的預測數據
成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
競爭定位、策略和市場佔有率分析
按業務板塊和地區（包括國家）分類的收入和預測評估
公司概況（策略、產品、財務資訊、關鍵發展等）

介紹
北美洲
- 美國
- 加拿大
- 墨西哥
南美洲
- 巴西
- 阿根廷
- 其他
歐洲
- 德國
- 法國
- 英國
- 西班牙
- 其他
中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
- 其他
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 印尼
- 泰國
- 其他

第11章競爭格局與分析

主要企業和策略分析
市佔率分析
合併、收購、協議和合作
競爭對手儀錶板

第12章：公司簡介

Thermo Fisher Scientific Inc.
ICON Plc
Charles River Laboratories International, Inc
IQVIA Holdings, Inc.
Syneos Health
SGS SA
Intertek Group Plc
Pace Analytical
Eurofins Scientific SE
BioPharma Services Inc.

第13章附錄

貨幣
先決條件
基準年和預測年時間表
相關人員的主要收益
調查方法
簡稱

簡介目錄

Product Code: KSI061615889

Bioanalytical Testing Market is forecasted to rise at a 15.7% CAGR, reaching USD 9.631 billion in 2031 from USD 4.014 billion in 2025.

The bioanalytical testing market is a critical and expanding component of the pharmaceutical and life sciences industry, underpinned by its essential role in drug development and personalized healthcare. This market encompasses the quantitative measurement of drugs, metabolites, biomarkers, and other analytes within biological matrices such as blood, plasma, urine, and tissues. Its sustained growth is driven by a convergence of scientific, medical, and industrial trends, including the shift towards personalized medicine, continuous technological innovation, and an escalating global pipeline of drug candidates and clinical trials.

A primary driver of market expansion is the accelerating demand for personalized medicine and biomarker-driven drug development. As therapeutic strategies increasingly focus on tailoring treatments to individual patient genetics, disease profiles, and predicted responses, the need for sophisticated bioanalysis becomes paramount. Bioanalytical testing is fundamental for identifying and validating biomarkers, quantifying target engagement, and understanding pharmacokinetic/pharmacodynamic (PK/PD) relationships in specific patient subpopulations. This shift from a one-size-fits-all model to precision medicine necessitates more complex, sensitive, and specific analytical methods, directly increasing the demand for advanced testing services and expertise to support targeted therapies and companion diagnostics.

Parallel to this, relentless advancements in analytical technologies are enhancing the capabilities and efficiency of bioanalytical testing. Innovations in instrumentation, such as high-resolution mass spectrometry (HRMS) and ultra-high-performance liquid chromatography (UHPLC), coupled with advanced ligand-binding assay platforms, are continuously improving assay sensitivity, specificity, and throughput. The integration of automation, robotics, and sophisticated data analytics streamlines workflows, reduces manual error, and accelerates time-to-result. These technological strides enable researchers to tackle more challenging molecules-including large biologics, cell and gene therapies, and oligonucleotides-and generate higher-quality data, thereby encouraging broader adoption and more ambitious applications in both research and regulated studies.

Furthermore, the market is propelled by the persistent rise in global drug development activity and the increasing prevalence of chronic diseases. The growing burden of conditions such as cancer, metabolic disorders, and cardiovascular diseases creates a urgent need for novel therapeutics. This, in turn, fuels a robust pipeline of preclinical and clinical programs, each requiring extensive bioanalytical support. Testing is indispensable across the entire development continuum, from early candidate screening and lead optimization to pivotal clinical trials and post-market monitoring. The expansion of clinical research, including complex trial designs and studies in diverse geographic regions, significantly amplifies the volume and geographic scope of testing requirements, providing a steady demand base for service providers.

Geographically, North America maintains a dominant position in the bioanalytical testing market. This leadership is attributed to the region's concentrated pharmaceutical and biotechnology research ecosystem, a high volume of clinical trial activity, and substantial investment in life sciences R&D. The presence of a mature network of large contract research organizations (CROs), specialized testing laboratories, and advanced academic research centers creates a dense and competitive service landscape. The region's well-defined regulatory pathways and early adoption of novel therapeutic modalities further reinforce its role as a primary hub for sophisticated bioanalytical work.

Despite strong growth drivers, the market faces significant restraints that impact operational and economic feasibility. Conducting bioanalytical testing to the stringent standards required for regulatory submissions involves high costs. These costs are driven by sophisticated instrumentation, highly skilled personnel, expensive reagents and reference standards, and the rigorous quality control and validation processes mandated by global health authorities. Additionally, access to specific and high-quality biological samples, particularly for rare diseases or unique patient populations, can be a logistical and ethical challenge, potentially delaying research. The complexity of navigating evolving regulatory requirements across different regions also adds to the operational burden and cost, demanding constant vigilance and adaptation from testing providers.

The competitive landscape is characterized by a mix of large, full-service CROs, specialized analytical laboratories, and the in-house capabilities of major pharmaceutical firms. Key differentiators include technological expertise in complex modalities, robust quality and compliance systems, global operational footprint, and the ability to provide integrated, end-to-end service offerings. The trend is toward forming strategic partnerships between sponsors and testing providers to leverage specialized expertise and manage capacity for large-scale or technically demanding programs.

In conclusion, the bioanalytical testing market is evolving in lockstep with the broader transformation of drug discovery and development. Its trajectory is firmly aligned with the industry's move towards precision medicine, complex biologics, and accelerated development pathways. Future growth will be sustained by ongoing technological innovation that pushes the boundaries of what can be measured and how quickly, coupled with the relentless pace of therapeutic R&D. Success for market participants will hinge on their ability to balance scientific excellence and regulatory rigor with operational efficiency, while continuously adapting to support the next generation of transformative therapies.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Bioanalytical Testing Market Segmentation

By Molecule Type
Small Molecule
Large Molecule
By Analysis Type
Discovery Bioanalysis
Pre-Clinical Bioanalysis
Clinical Bioanalysis
By Sample Type
Blood
Urine
Saliva
Plasma
Others
By Application
Oncology
Neurology
Immunology
Metabolic Disorder
Infectious Disease
Others
By End-User
Pharmaceuticals & Biotech Company
Contract Research Organization
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. BIOANALYTICAL TESTING MARKET BY MOLECULE TYPE

5.1. Introduction
5.2. Small Molecule
5.3. Large Molecule

6. BIOANALYTICAL TESTING MARKET BY ANALYSIS TYPE

6.1. Introduction
6.2. Discovery Bioanalysis
6.3. Pre-Clinical Bioanalysis
6.4. Clinical Bioanalysis

7. BIOANALYTICAL TESTING MARKET BY SAMPLE TYPE

7.1. Introduction
7.2. Blood
7.3. Urine
7.4. Saliva
7.5. Plasma
7.6. Others

8. BIOANALYTICAL TESTING MARKET BY APPLICATION

8.1. Introduction
8.2. Oncology
8.3. Neurology
8.4. Immunology
8.5. Metabolic Disorder
8.6. Infectious Disease
8.7. Others

9. BIOANALYTICAL TESTING MARKET BY END-USER

9.1. Introduction
9.2. Pharmaceuticals & Biotech Company
9.3. Contract Research Organization
9.4. Others

10. BIOANALYTICAL TESTING MARKET BY GEOGRAPHY

10.1. Introduction
10.2. North America
- 10.2.1. USA
- 10.2.2. Canada
- 10.2.3. Mexico
10.3. South America
- 10.3.1. Brazil
- 10.3.2. Argentina
- 10.3.3. Others
10.4. Europe
- 10.4.1. Germany
- 10.4.2. France
- 10.4.3. United Kingdom
- 10.4.4. Spain
- 10.4.5. Others
10.5. Middle East and Africa
- 10.5.1. Saudi Arabia
- 10.5.2. UAE
- 10.5.3. Israel
- 10.5.4. Others
10.6. Asia Pacific
- 10.6.1. China
- 10.6.2. India
- 10.6.3. Japan
- 10.6.4. South Korea
- 10.6.5. Indonesia
- 10.6.6. Thailand
- 10.6.7. Others